A Heart Valve That Grows With a Child: Is It Real?
The FDA has approved Autus, the first synthetic pulmonary heart valve designed to grow with a child. A toddler can have it implanted at about 13 mm, and over the years a cardiologist can thread a balloon catheter up to it and widen it to about 22 mm, without opening the chest again. For families staring down a childhood of sternotomies, that is a real, if partial, breakthrough. It is a bridge through childhood, not a lifetime valve.
On October 1, 2026, the FDA cleared the Autus Size-Adjustable Valve for children with congenital pulmonary valve disease. It is the first pediatric heart valve designed to be enlarged after it is implanted, and the first US-approved heart valve whose leaflets are synthetic polymer rather than animal tissue. The valve is sewn in during open-heart surgery at a diameter sized to the child. As the child grows, a cardiologist can pass a balloon up through a vein in the groin, inflate it inside the frame, and widen the valve to keep up with the heart. The approved range spans roughly 13 mm at implant to about 22 mm after expansion, which covers the span from a toddler-sized pulmonary valve to an adult one.
Why a growing valve matters here
The problem Autus is trying to solve is not that pulmonary valves fail. It's that children outgrow them. A valve replaced in a two-year-old was never going to fit a twelve-year-old's heart. So the standard path for a child born with tetralogy of Fallot, pulmonary atresia, or truncus arteriosus has been to accept a cycle of open-heart redos: implant a fixed valve, let the child grow out of it, open the chest, swap it, and do it again.
The published numbers on fixed valves show how fast that cycle runs. At five years, around 90 to 95 percent of children have not needed another intervention. By ten years, that drops to roughly half to two thirds. Children under 18 face about five times the reintervention risk of adults getting the same valve. A single pulmonary valve replacement in a small child is rarely a single operation; it's the first of several.
How the valve is widened without surgery
Autus is implanted the first time through a standard open-heart operation on bypass. What changes is what happens afterward. Instead of growing out of the valve and needing another sternotomy, the child can go to the cath lab. The cardiologist threads a catheter with a balloon on its tip up to the valve, inflates it inside the frame, and the frame expands. The synthetic leaflets stay competent at the new diameter. The child goes home the next day, chest closed.
The approval rests on two separate studies. An earlier US early feasibility study, published in 2025, implanted the valve in 11 children aged 2.7 to 13.9 years across three centers, adjusted it intraoperatively between 14 and 20 mm, and reported no deaths, no device-related adverse events, no thrombus, and no endocarditis at one year, with 10 of 11 children showing no pulmonary regurgitation. The pivotal study the FDA used for approval was larger but shorter: across twelve US centers, 62 children received the valve, with the primary endpoint at six months. Through six months, no child died, had a stroke, or had a clot, and all were free of device-related complications at 30 days. Two children who began to outgrow their valve were taken to the cath lab and re-expanded without surgery, which is the core promise of the device, demonstrated in patients.
What the trial does not yet tell us
The ceiling on this news is time. The pivotal primary endpoint was at six months. Pediatric valves tend to look good at one year and start to deteriorate between years five and ten, which is exactly the window the pivotal data cannot yet speak to. Three of the 62 children had frame fractures, and two had reduced leaflet motion. Those are the early warning signs that will matter when post-approval studies hit five and ten years.
The broader literature on growth-accommodating valves is also sobering. Earlier expandable designs built on bovine jugular vein tissue did allow serial balloon dilations and lower gradients, but perivalvular leaks, structural deterioration, and infective endocarditis still forced surgical revision in a meaningful share of children. Autus uses synthetic leaflets, which is one reason to hope it does better on tissue degeneration and endocarditis. It is not a reason to assume it will.
Where Autus fits among the other options
| Valve type | How reinterventions happen | Durability in children |
|---|---|---|
| Autus size-adjustable synthetic valve | Open-heart implant, then balloon catheter re-expansion in the cath lab from about 13 mm toward 22 mm | Six-month pivotal data in 62 children: no deaths, strokes, or clots; long-term durability still being tracked |
| Surgical bioprosthetic valve | Open-heart redo each time the valve fails or is outgrown | Reintervention-free at five years about 90 to 95 percent; drops to roughly half to two thirds by ten years |
| Cryopreserved pulmonary homograft | Open-heart redo when the valve deteriorates or is outgrown | Among the most durable biologic options; freedom from structural deterioration around 85 to 88 percent at ten years in children |
| Melody transcatheter valve | Placed by catheter inside a prior conduit; redilated or re-stented by catheter when it narrows | In children weighing 30 kg or less, freedom from any pulmonary reintervention at ten years is about 46 percent; endocarditis is higher than with homografts |
Read the table as a trade. Homografts last longer than most options but do not grow, so a small child gets a conduit they will outgrow. Melody is already catheter-based but is placed inside a surgical conduit that had to go in first, and it carries a higher endocarditis signal. Autus is the first device whose first implant is sized to a small child and whose later enlargements do not require opening the chest.
Who this changes care for, and who it does not
If your child is facing pulmonary valve replacement, especially a young or small child likely to need multiple reoperations, Autus is now a real option to raise with your pediatric cardiac team. The question to ask is specific: is my child's anatomy and diagnosis within the label, and does your center implant Autus. The approval route was the FDA's Total Product Life Cycle Advisory Program, a pilot meant to speed innovative devices to market, and the earliest implanting centers are the twelve pivotal trial sites. Access will spread from there.
Autus does not change the plan for children whose problem is on the aortic side, who need a conduit rather than a valve, or whose anatomy falls outside the approved indication. It does not remove the need for lifelong cardiology follow-up. And it does not end heart surgery for congenital heart disease; children who outgrow Autus by their late teens will still face a surgical revision as adults, because the device tops out around an adult pulmonary valve size.
The judgment
The right way to think about Autus is as a bridge through childhood. It trades some open-heart redos for cath lab visits during the years when children grow the fastest, with a safety profile strong enough for the FDA to approve it on 62 patients and six months of primary data. What it has not yet shown is how long the synthetic leaflets, the frame, and the sutured ring will hold up over the decade when previous pediatric valves have started to fail. Five- and ten-year post-approval data on frame fracture, leaflet failure, endocarditis, and how often the valve actually gets re-expanded will decide whether Autus is a better valve or just a cleverer one. For a family looking at a childhood of sternotomies today, that is still worth asking about.